Maybe doing this step after freezing is actually less efficient than doing so before freezing and maybe cell selection and exposure to lysate before freezing for storage is even more efficacious and creates greater viability cell count than doing so afterwards. You know like what might be tested for in an equivalence validation process that likely was done loooooonnnnngggg ago hence the claim of sameness by Dr. Linda Liau?; ). You don’t seem to do too well with putting puzzle pieces together correctly. So glad the Lindas and others whose opinions matter in the approval process are good at this. Best wishes.
I think the ATL DC manufacturing by UCLA is on a small scare whereas the ATL DC manufactured by NWBO can be configured to be on a vary large scale once the approvals are announced. That's the only difference. This topic by the fudster-extraordinaire is ancient. The fudster is reduced to docile fud after the publication of the JAMA data.
I normally don't waste my time posting here anymore because of too many dunning-kruger 'experts' like flipper.
I always had you as a someone retired but expert in the field - Here just out of general interest - you're one of the few that genuinely know your shit when it comes to the stats. But my god your desperation shows who you really are (if you're even one person).
As you know but conveniently ignore you infringe on a patent if you use every component of a particular claim. Go through claim 1 of the family of dcvaxl patents. The minor differences of atl-dc do not deviate in the slightest from claim 1 of the dcvaxl patents. I.e dcvax-l claim1 describes atl-dc.
You guys are just trying to scare a few Newby investors!what a joke!
DCVAX-L uses a manufacturing process that makes a separate batch for every patient If you have a real point to make please make it and be specific because these statements as is are nonsense